Coeptis Therapeutics (COEP) Stock Price, News & Analysis

Company Overview

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Key Stats

• Today's Range: $0.19 to $0.21
• 50-Day Range: $0.16 to $0.23
• 52-Week Range: $0.15 to $1.28
• Volume: 255,307 shs
• Average Volume: 310,057 shs
• Market Capitalization: $8.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

COEP Stock Analysis - Frequently Asked Questions

How have COEP shares performed this year?

Coeptis Therapeutics' stock was trading at $0.7839 at the beginning of 2024. Since then, COEP stock has decreased by 75.2% and is now trading at $0.1946.
View the best growth stocks for 2024 here.

How were Coeptis Therapeutics' earnings last quarter?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) announced its quarterly earnings results on Friday, August, 16th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01.

How do I buy shares of Coeptis Therapeutics?

Shares of COEP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Coeptis Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Coeptis Therapeutics investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), PayPal (PYPL), Tesla (TSLA), Meta Platforms (META), 3M (MMM) and PHX Minerals (PHX).

Company Calendar

• Last Earnings: 8/16/2024
• Today: 11/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:COEP
• CUSIP: N/A
• CIK: 1759186
• Web: coeptispharma.com
• Phone: 724-934-6467
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-21,270,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,094.50%
• Return on Assets: -219.97%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 0.40
• Quick Ratio: 0.40

Sales & Book Value

• Annual Sales: $80,000.00
• Price / Sales: 100.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.12 per share
• Price / Book: 1.62

Miscellaneous

• Outstanding Shares: 41,120,000
• Free Float: 31,148,000
• Market Cap: $8.00 million
• Optionable: Not Optionable
• Beta: -0.94